MDxHealth

MDxHealth is a multinational molecular diagnostics company headquartered in Herstal, Belgium, with additional offices in Irvine, California, and Nijmegen, the Netherlands. Founded in 2003, the company develops and commercializes advanced epigenetic tests aimed at cancer assessment and personalized treatment. Its product offerings include ConfirmMDx, a prostate cancer test that addresses false-negative biopsy concerns; SelectMDx, a non-invasive urine test for guiding repeat biopsies; and AssureMDx, a non-invasive liquid biopsy test for bladder cancer decision-making. The company also provides PredictMDx for Glioblastoma, a tissue methylation test for brain cancer treatment decisions. MDxHealth's proprietary technologies assist physicians in diagnosing urologic cancers, assessing recurrence risks, and predicting treatment responses. The company generates revenue through clinical laboratory testing services and the out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.